During the past 12 months, Oncodesign Precision Medicine's average Total Assets Growth Rate was 136.70% per year.
During the past 3 years, the average Total Assets Growth Rate was 37.10% per year.
During the past 5 years, the average Total Assets Growth Rate was 23.80% per year.
During the past 6 years, Oncodesign Precision Medicine's highest 3-Year average Total Assets Growth Rate was 37.10%. The lowest was 16.40%. And the median was 16.50%.
Note:
The Net Income data used here is two times the semi-annual (Dec. 2025) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Oncodesign Precision Medicine's Asset Turnover for the quarter that ended in Dec. 2025 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Oncodesign Precision Medicine Total Assets Related Terms
Oncodesign Precision Medicine Total Assets Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncodesign Precision Medicine Total Assets Calculation
Total Assets are all the assets a company owns.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncodesign Precision Medicine (FRA:ZR8) has a Total Assets of €14.99 Mil as of Dec. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on Oncodesign Precision Medicine and its competitors.
Is Oncodesign Precision Medicine's Total Assets too high?
Oncodesign Precision Medicine's current Total Assets is €14.99 Mil. Overall, Oncodesign Precision Medicine has a GF Score™ of 38/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Oncodesign Precision Medicine's Total Assets compare to VRTX and REGN?
Oncodesign Precision Medicine's Total Assets of €14.99 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Oncodesign Precision Medicine and its competitors. Oncodesign Precision Medicine's current Total Assets is €14.99 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncodesign Precision Medicine stock overvalued right now?
Based on GuruFocus' analysis, Oncodesign Precision Medicine (FRA:ZR8) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.26, compared to a current price of €0.30 — trading 16.9% above its estimated fair value. The current Total Assets is €14.99 Mil. Oncodesign Precision Medicine's overall GF Score™ is 38/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Oncodesign Precision Medicine (FRA:ZR8), the current Total Assets is €14.99 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncodesign Precision Medicine (FRA:ZR8) Overvalued in 2026?
Based on GuruFocus' analysis, Oncodesign Precision Medicine stock appears to be overvalued.
The current stock price of €0.30 is trading 16.9% above its estimated GF Value™ of €0.26.
GuruFocus considers Oncodesign Precision Medicine to be Modestly Overvalued.
Key valuation signals for FRA:ZR8:
Total Assets: €14.99 Mil
GF Value™: €0.26 vs. price of €0.30 (16.9% above fair value)
No single metric tells the full story. See the FRA:ZR8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oncodesign Precision Medicine Business Description
Oncodesign Precision Medicine SA is a biopharmaceutical company specialised in precision medicine. Its mission is to provide patients with effective diagnostic and therapeutic solutions for resistant and metastatic cancers.
38GF Score
Get the complete analysis for FRA:ZR8
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:ZR8 has been successfully added to your 
